194 results about "Sildenafil" patented technology

The present invention is directed to nanoparticulate compositions comprising sildenafil free base. The sildenafil free base particles of the composition have an effective average particle size of less than about 2000 nm.

Multiple agent therapy for treatment of sexual dysfunction, including male erectile dysfunction, with sequential administration a type V phosphodiesterase inhibitor (PDE-5), such as sildenafil, preferably wherein the PDE-5 inhibitor is administered by oral dose means, and a melanocortin 3 and/or 4 receptor agonist, such as Ac-Nle-cyclo(-Asp-His-D-Phe-Arg-Trp-Lys)-OH (PT-141) preferably wherein the PT-141 is formulated for and administered by intranasal means, and further preferably wherein the PDE-5 inhibitor is administered prior to PT-141.

Sildenafil, a known pharmaceutical chemical useful in treatment of male sexual dysfunction, is prepared by processes in which the final chemical intermediate is of significantly lower basicity than sildenafil itself, so that sildenafil can be extracted in substantially pure form from the organic reaction mixture in which it is made by adding an aqueous medium of appropriately chosen acidic pH and causing phase shift of the sildenafil to occur selectively into the aqueous phase.

Provided are processes for the preparation of sildenafil base and the citrate salt sildenafil. Also provided are sildenafil citrate water adduct and a method of preparing pharmaceutical compositions comprising combining the sildenafil citrate and/or sildenafil citrate water adduct with at least one pharmaceutically-acceptable excipient.

A class of cGMP PDE inhibitors, including sidenafil and pharmaceutically acceptable salts thereof, which can be used to treat sexual dysfunction in male and female animals, especially humans, with a spinal cord injury. The invention can be used to treat sexual dysfunction in male animals that exhibit essentially no residual penile function.

The present disclosure is directed to chemically-stable and pharmaceutically-acceptable sildenafil oral spray formulations for the treatment of male erectile dysfunction, wherein the oral spray formulation has a pH of about 1.5 to less than 3.0. The present disclosure is also directed to methods for treating male erectile dysfunction.

Modified release formulations comprising at least one of modafinil and sildenafil, and combinations thereof, and a time-controlled delivery system coating.

The invention discloses a technique for artificially synthesizing antigen of Sildenafil and derivative thereof, which comprises the following steps: generating water-soluble EDC, balancing EDC, NHS, DMF and hapten compound to room temperature, weighting EDC, NHS and hapten compound, adding the weighted sample into a clean round bottomed flask, adding DMF, dissolving and marking the generated solution as No.2 reaction solution, dissolving carrier protein in boric acid buffer solution with a ratio of 1:0.15 to 0.2 in another clean container, turning into another clean round bottomed flask and marking the solution as No.3 reaction solution, adding the No.2 reaction solution into the No.3 reaction solution, dialyzing the samples after finishing reaction, cooling and drying the samples into white flocculent products, namely the artificially synthesized antigen.

The invention discloses a method to test Sildenafil citrate and its ramifications. It contains steps: (1) Color reaction. Make color reaction of test sample with bismuth potassium iodide, silico-tungstic acid and Hager's reagent to observe result. (2) Result estimation. If above three color reactions appear deposit, there are Sildenafil citrate and its ramifications in test samples. If just one, two or none color reaction appear deposit, there is no Sildenafil citrate and its ramifications in test samples. The method has merits of quick, simple, strong property, high accuracy, extensive application and testing range.

The invention discloses a medicinal composition containing sildenafil citrate and PD-1 type pregelatinized starch and a preparation method thereof. The medicinal preparation prepared from the medicinal composition containing the sildenafil citrate and the PD-1 type pregelatinized starch and the preparation method provided by the invention can be completely disintegrated in water at a degree of 37 DEG C within 15 to 30 seconds, and can pass through a screen in a size of 600 to 710 mu m.

The invention relates to the technical field of medicine, in particular to a quinazolinone derivative, a preparation method and application thereof. The invention discloses quinazolinone compounds as structural general formula (I) or pharmaceutically acceptable salt thereof. Most of the compounds have stronger PDE5 inhibition activity than that of Sildenafil, and have higher selectivity than thatof PDE 6 distributed on a retina. Therefore, the compounds are expected to show better clinical safety and effectiveness, and have wide clinical application prospect.

A method is provided for the prevention of ischemia/reperfusion injury, for example, in patients undergoing heart surgery, and involves the administration of a phosphodiesterase-5 (PDE-5) inhibitor such as sildenafil. The method may also be used during or after a heart attack to prevent or lessen ischemic heart damage.

The invention discloses a sildenafil citrate sublingual tablet and a preparation method thereof. The sildenafil citrate sublingual tablet is prepared from 1 part by weight of sildenafil citrate and 4 to 8 parts by weight of pharmaceutical adjuvant , wherein the pharmaceutical adjuvant comprises 2 to 4 percent of disintegrant, 94 to 96 percent of diluter, 0.5 to 1.2 percent of lubricator, 0.3 to 1 percent of corrective and 0.1 to 0.2 percent of binder, which are based on the total weight of the pharmaceutical adjuvant. Test results show that the prepared sublingual tablet has shorter disintegration time, higher dissolving speed in vitro and higher body bioavailability than the conventional tablets.

Provided is a fast dissolving film composition comprising a medically active component as an active ingredient, in which the bitter taste of the active ingredient is masked and the fast dissolving film composition has a high content of 50% or higher. More particularly, provided is a pharmaceutical composition which comprises sildenafil or pharmaceutically acceptable salts thereof as an active ingredient, and which comprises a combination of a specific bitter taste masking agent to achieve masking of a bitter taste. Further, provided is a fast dissolving film composition which comprises a combination of a specific plasticizer to mask a bitter taste, and in which the physical properties of the high-content film are excellent.

A sildenafil citrate taste-masking preparation and a preparing method thereof are disclosed. The sildenafil citrate taste-masking preparation at least comprises, based on the total weight of tablets, 15-30% of sildenafil citrate, 30-65% of hydroxypropyl cellulose and 15-20% of glyceryl behenate. The preparing method includes: mixing a formula dosage of the sildenafil citrate and a formula dosage of the hydroxypropyl cellulose to prepare melt dispersion, cutting the melt dispersion into particles, grinding the particles together with the glyceryl behenate, fully mixing with other auxiliary materials, and tabletting into tablets for oral administration.

The invention relates to cydiodine buccal tablets and a preparation method thereof. The cydiodine buccal tablets comprise the following components in percentage by mass: 0.1 to 6 percent of cydiodine,0.5 to 5 percent of sildenafil, 0 to 2 percent of lubricant, and 84.4 to 98.5 percent of filler. The filler is one or combination of the following components: mannitol, lactose, xylitol, sorbitol, erythritol, fructose, isomalt, dextrin, microcrystalline cellulose, starch, pregelatinized starch, sodium chloride. The invention also proposes a method for preparing the buccal tablets, which comprisesthe following steps: preparing cydiodine and sildenafil; weighing the components according to proportioning rate, granulating and mixing the components; determining the content of every component inmixed medicaments and calculating the weight difference of products; and tabletting the mixed medicament. In the process of treating oral or other diseases, the cydiodine buccal tablets prepared by the method have the advantages of reducing the amount of sucrose taken in by patients and reducing harm to the patients.

The invention belongs to the technical field of immunodetection and discloses a sildenafil and its analogue immunodetection method. An artificial antigen is prepared from a mercapto-sildenafil hapten, and an antibody is prepared by the artificial antigen and is used for detecting sildenafil and its analogue. The method solves the problems of the existing sildenafil detection technology, has the largest sildenafil detection range of 0.024-1.21ng/mL, sensitivity of 0.17ng/mL, a detection limit of 0.008ng/mL and a recovery rate of 86.0-90.8%, has a fast detection rate, greatly shortens detection time, is not influenced by an operator proficiency degree, can be finished in about 80min, and has a low detection limit and high sensitivity.

The invention belongs to the technical field of medicinal chemistry, relates to a purification method for high-purity sildenafil freebases, particularly to a purification method for removing new impurities from the sildenafil freebases. The method includes adding 1-6 times (v/w) of organic solvents to sildenafil freebase (II) crude products, stirring fully, warming to 40-60DEG C, stirring for 1-6h with temperature preservation, then cooling to the room temperature, filtering and drying to obtain sildenafil freebase (II) fine products.

This invention relates to the use of cyclic guanosine 3′,5′-monophosphate phosphodiesterase type five inhibitors, including in particular the compound sildenafil, for the treatment of premature ejaculation in patients with normal erectile function.